加拿大医院厄他培南耐药肠杆菌17年监测特征
CPE对头孢他啶/阿维巴坦、亚胺培南/瑞来巴坦和美罗培南/伐博巴坦的耐药率为20.8%至25.0%,非CPE为2.7%至4.5%。
要点
- 加拿大厄他培南耐药肠杆菌仍少见,17年监测耐药率仅0.7%。
- 厄他培南耐药株中CPE占17.9%,以KPC型为主(62.5%)。
- CPE对多种新型β-内酰胺酶抑制剂复方耐药率高于非CPE。
核心结论
- 加拿大厄他培南耐药肠杆菌不常见(0.7%),CPE对多种抗菌药物耐药率更高且携带更多耐药基因,需持续监测。
主要发现
- 134株(0.7%)对厄他培南耐药,其中CPE 24株(17.9%),以肺炎克雷伯菌(54.2%)和大肠埃希菌(20.8%)为主。
- CPE中最常见碳青霉烯酶为KPC(62.5%),常见ST包括肺炎克雷伯菌ST834、ST16、ST258和大肠埃希菌ST131。
- 非CPE厄他培南耐药株以肠杆菌属(51.8%)、大肠埃希菌(15.5%)和肺炎克雷伯菌(10.9%)为主,常见ST为阴沟肠杆菌ST108、ST50、ST133和大肠埃希菌ST131。
- CPE对头孢他啶/阿维巴坦、亚胺培南/瑞来巴坦和美罗培南/伐博巴坦的耐药率为20.8%至25.0%,非CPE为2.7%至4.5%。
- 大多数非CPE分离株至少携带一种AmpC、ESBL或孔蛋白改变。
关键数值与推荐
- CPE占厄他培南耐药株的17.9%(24/134),KPC占CPE的62.5%。
- CPE对头孢他啶/阿维巴坦、亚胺培南/瑞来巴坦和美罗培南/伐博巴坦的耐药率为20.8%至25.0%。
- 非CPE对上述三种复方制剂的耐药率为2.7%至4.5%。
临床怎么用
- 临床遇到厄他培南耐药肠杆菌时应警惕CPE可能,尤其是肺炎克雷伯菌和大肠埃希菌。
- CPE对新型β-内酰胺酶抑制剂复方仍有一定耐药率,治疗前应进行药敏试验。
- 非CPE耐药株多由AmpC、ESBL或孔蛋白改变介导,需关注其耐药机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review phenotypic and genotypic characteristics of ertapenem-resistant Enterobacterales isolates identified by the CANWARD study from 2007 to 2023. METHODS: Bacterial isolates were collected as part of the CANWARD surveillance study from 2007 to 2023. CLSI M7 broth microdilution antimicrobial susceptibility testing (12th edition, 2024) was performed. MICs were interpreted by CLSI M100 breakpoints (34th edition, 2024). WGS was performed to identify antimicrobial resistance markers. RESULTS: Only 134 (0.7%) of the 19 642 Enterobacterales were ertapenem-resistant. Carbapenemase producing Enterobacterales (CPE) accounted for 17.9% (n = 24) of ertapenem-resistant isolates and were predominantly Klebsiella pneumoniae (54.2%) and Escherichia coli (20.8%). KPC was the most common carbapenemase identified (62.5%). K. pneumoniae ST834, ST16 and ST258, and E. coli ST131 were the most frequent STs detected. CPE percent resistant values ranged from 20.8% to 25.0% for ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam. Most non-CPE ertapenem-resistant isolates were Enterobacter spp. (51.8%), E. coli (15.5%) and K. pneumoniae (10.9%). Non-CPE STs were most commonly E. cloacae ST108, ST50 and ST133, and E. coli ST131. Non-CPE percent resistant values ranged from 2.7% to 4.5% for ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam. At least one of an AmpC, an ESBL or porin alternations were observed in most non-CPE isolates. CONCLUSIONS: In Canada, ertapenem-resistant Enterobacterales remain uncommon (0.7%). CPE isolates demonstrated higher percent resistant values for multiple antimicrobial classes and harboured more antimicrobial resistance genes than non-CPE isolates. Continued monitoring for ertapenem-resistant Enterobacterales, particularly CPE, is important given their associated multidrug resistance to both established and newer agents.
引用
- Mataseje LF, Lerminiaux N, Lagacé-Wiens P, et al. Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007-23). J Antimicrob Chemother. 2025. PMID: 40873030. doi:10.1093/jac/dkaf221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。